Phase 1 two-part, randomized, double-blind, placebo-controlled dose-escalation SAD/MAD study of VTX-958
Latest Information Update: 19 Aug 2022
At a glance
- Drugs VTX-958 (Primary)
- Indications Autoimmune disorders
- Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics
- 15 Aug 2022 Results published in the Ventyx Biosciences Media Release.
- 11 Aug 2022 According to a Ventyx Biosciences media release, the company to host a conference call and webcast to discuss topline results from this study on 15 Aug, 2022.
- 23 Mar 2022 According to a Ventyx Biosciences media release, the company expect to complete dosing of the last subject in the second quarter of 2022. Topline data from this trial expected in the early Q3 2022.